

October 21, 2024
Japan System Techniques Co., Ltd.

Investment in Exosome Research Biotech Company Regenesome

Support for solving issues relating to progress for the future of health care with Kengo Suzuki, the co-founder of Euglena

Japan System Techniques Co., Ltd. (“JAST”) has made a pre-seed round investment in Regenesome Inc., a biotech startup company based in Tokyo, and purchased its J-KISS type stock acquisition rights in the amount of 80 million yen. The company’s CEO is Kengo Suzuki and President and Representative Director is Zentarō Sakuma.

■ Profile of Regenesome

Name: Regenesome Inc.
Representatives: Kengo Suzuki, CEO
Zentarō Sakuma, President and Representative Director
Head office: Minato-ku, Tokyo
Established: July 12, 2024
Website: <https://ss-hd.co.jp/regenesome>
Business: Research and development of exosomes
Parent Company: Space Seed Holdings Co., Ltd. (CEO Kengo Suzuki)

■ For More Information

Inquiries

Japan System Techniques Co., Ltd.
The Future Co-Creation Laboratory
Contact: Ichihara, Choi
TEL: +81-3-6718-2785
Mail: JAST-Lab@jast.co.jp
URL: <https://www.jastlab.jast.jp/>

For media inquiries

Japan System Techniques Co., Ltd.
General Affairs & Human Resources Department
Contact: Yamashita, Ishida
TEL: +81-6-4560-1000
Mail: press@jast.co.jp
URL: <https://www.jast.jp/>